(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Our favorite Space.com stories of 2025 - 2Sexual violence is being used as a weapon in Sudan's war, doctors group says
- 3What to know about Jack Dorsey's new Vine revival, DiVine
- 4Archaeologists uncover details about the Hjortspring boat's origins
- 5'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity
- Israel says 40 Hezbollah members killed as forces advance in Lebanon
- French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
- 5 Advancement Developments in Biotechnology
- Amateur's Manual for Venture Strategies for Tenderfoots
- ICAS calls for clearer safeguards in FRC’s TCA policy
- Vote In favor of Your #1 Compelling Female Producer
- Vote in favor of your Number one natural product
- Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
